Toenail onychomycosis in patients with acquired immune deficiency syndrome: Treatment with terbinafine

British Journal of Dermatology

Volumn 137, Issue 4, 1997, Pages 577-580

  Herranz, P ^a   Garcia J ^a   De Lucas, R ^a   Gonzalez J ^a   Pena J M ^a   Diaz R ^a   Casado, M ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

TERBINAFINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIFUNGAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION RISK; MALE; NAIL; ONYCHOMYCOSIS; PRIORITY JOURNAL; TOE; TREATMENT OUTCOME;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; FEMALE; FOLLOW-UP STUDIES; FOOT DERMATOSES; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; ONYCHOMYCOSIS; TREATMENT OUTCOME;

EID: 0030815340     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1997.tb03789.x     Document Type: Article

References (29)

1. Goodman DS, Teplitz DE, Wishner A et al. Prevalence of cutaneous disease in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex. J Am Acad Dermatol 1987; 17: 210-20.
2. Prose NS, Abson KG, Scher RK. Disorders of the nails and hair associated with human immunodeficency virus infection. Int J Dermatol 1992; 31: 453-7.
3. Matis WL, Triana A, Shapiro R et al. Dermatologic findings associated with human immunodeficiency virus infection. J Am Acad Dermatol 1987; 17: 746-51.
4. Kaplan MH, Sadick N, McNutt NS et al. Dermatologic findings and manifestations of acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol 1987; 16: 485-506.
5. Conant MA. The AIDS epidemic. J Am Acad Dermatol 1994; 31: S47-50.
6. Gregory N. Special populations: onychomycosis in the HIV-positive patient. J Am Acad Dermatol 1996; 35: S13-16.
7. Daniel III CR, Norton LA, Scher RK. The spectrum of nail disease in patients with human immunodeficiency virus infection. J Am Acad Dermatol 1992; 27: 93-7.
8. Cockerell CJ. Human immunodeficiency virus and the skin. A crucial interface. Arch Intern Med 1991; 151: 1259-303.
9. Goodfield MJD. Short duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. Br J Dermatol 1992; 126 (Suppl. 39): 33-5.
10. Faergemann J, Anderson C, Hersle K et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995: 32: 750-3.
11. van Der Schroeff JG, Cirkel PKS, Crijins MB et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992; 126 (Suppl. 39): 36-9.
12. Baudraz-Rossele F, Rakosi T, Wili PB, Kenzelmann R. Treatment of onychomycosis with terbinafine. Br J Dermatol 1992; 126 (Suppl. 39): 40-6.
13. Shear NH, Gupta AK. Terbinafine for the treatment of pedal onychomycosis. Arch Dermatol 1995; 131: 937-42.
14. Finlay AY. Global overview of Lamisil®. Br J Dermatol 1994; 130 (Suppl. 43): 1-3.
15. Scher RK. Onychomycosis is more than a cosmetic problem. Br J Dermatol 1994; 130 (Suppl. 43): 15.
16. Scher RK. Onychomycosis: a significant medical disorder. J Am Acad Dermatol 1996; 35: S2-S5.
17. Wright C, Lennax JL et al. Generalized chronic dermatophytosis in patients with human immunodeficiency virus type 1 infection and CD4 depletion. Arch Dermatol 91; 127: 265-6.
18. Grossman ME, Pappert AS, Garzon MC, Silvers DN. Invasive Trichophyton rubrum infection in the immunocompromised host: report of three cases. J Am Acad Dermatol 1995: 33: 315-8.
19. La Placa Jr M, Stinchi C, Tosti A et al. Terbinafine treatment of onychomycosis in patients with hepatic disease or in organ transplant recipients. J Dermatol Treat 1995; 6: 51-2.
20. Marchese LM, Cucé LC, Chocair PR, Sabbaga E. Efficacy and safety of terbinafine by oral route in the treatment of onychomycosis in renal transplanted patients. J Eur Acad Dermatol Venereol 1996; 70 (Suppl. 2): S95.
21. Nanwani R, Parnell A, Youle M et al. Use of terbinafine in HIV-positive subjects: pilot studies in onychomycosis and oral candidiasis. Br J Dermatol 1996; 134 (Suppl. 46): 22-4.
22. Tosti A, Piraccini BM, Stinchi C, Venturo N, Colombo MD. Relapse rate of onychomycosis after systemic treatment with terbinafine or itraconazole: a 2-year follow-up. J Eur Acad Dermatol Venereol 1996; 7 (Suppl. 2): S157.
23. White JE, Perkins JP, Evans EGV. Successful 2-week treatment with terbinafine (Lamisil®) for moccasin tinea pedis and tinea manuum. Br J Dermatol 1991; 125: 260-2.
24. Breckeridge A. Clinical significance of interactions with antifungal drugs. Br J Dermatol 1992; 26 (Suppl. 39): 19-22.
25. Piscitelli SC, Flexner C, Minor JR et al. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 23: 685-93.
26. Coopman SA, Stern RS. Cutaneous drug reactions in human immunodeficiency virus infection. Arch Dermatol 1991; 127: 714-7.
27. Brody N. Cutaneous fungal infection: innovative treatment schedules with systemic agents. Int J Dermatol 1995; 34: 284-9.
28. Lake-Baakar G, Tom W, Lake-Baakar D et al. Gastropathy and ketoconazole malabsortion in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988; 109: 471-3.
29. Contini C, Manganaro M, Romani R et al. Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia. J Antimicrob Chemother 1994; 34: 727-35.